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Abstract
Purpose Respiratory distress is the primary driver for heart
failure (HF) hospitalization. Implantable pacemakers and de-
fibrillators are capable of monitoring respiratory rate (RR) in
ambulatory HF patients. We investigated changes in RR prior
to HF hospitalizations and its near-term risk stratification
power.
Methods NOTICE-HF was an international multi-center
study. Patients were implanted with an implantable
cardioverter defibrillator or cardiac resynchronization therapy
defibrillator, capable of trending daily maximum, median, and
minimum RR (maxRR, medRR, minRR). RR from 120 pa-
tients with 9 months of follow-up was analyzed. One-tailed
Student’s t test was used to compare RR values prior to HF
events to baseline defined as 4 weeks prior to the events. A
Cox regression model was used to calculate the hazard ratios
(HR) for the 30-day HF hospitalization risk based on RR
values in the preceding month.
Results Daily maxRR,medRR, andminRRwere significantly
elevated prior to HF events compared to baseline (ΔmaxRR
1.8±3.0; p=0.02; ΔmedRR, 2.1±2.8; p=0.007; ΔminRR,
1.5±2.1, p=0.008). Risk of experiencing HF events within
30-days was increased if the standard deviation of medRR
over the preceding month was above 1.0 br/min (HR=12.3,
95 % confidence interval (CI) 2.57–59, p=0.002). The risk
remained high after adjusting for clinical variables that dif-
fered at enrollment.
Conclusion Ambulatory daily respiratory rate trends may be a
valuable addition to standard management for HF patients.
Keywords Implantable device . Respiratory rate . Heart
failure . Risk stratification
1 Introduction
Respiratory distress is common in heart failure (HF) patients
[1, 2] and is the primary driver for HF hospitalization. The
with some type of dyspnea and 36 % with dyspnea at rest at
HF admission [3]. Respiratory distress is also associated with
worse clinical outcomes. Respiratory symptoms such as
breathlessness and orthopnea are significantly related to in-
creased mortality and hospitalization [4, 5]. Rapid respiratory
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ADHERE® registry showed that 89 % of patients presented
rate (RR) has been shown to be a predictor of increased risk
for hospitalization and mortality [6, 7]. A method for reliably
detecting early respiratory distress may allow identification of
patients at high risk of decompensation and thereby trigger
timely patient care and intervention.
When patients complain of dyspnea, their breathing is often
rapid and shallow [8–11]. Although HF patients have a higher
respiratory rate than normal controls, both during stable pe-
riods [11] and during acute decompensation [12], relatively,
little is known about respiratory rate changes leading up to
worsening HF largely due to the difficulty of ambulatory re-
spiratory monitoring. Charachet al. [8] demonstrated that re-
spiratory rate often increased during the evolving stage of
cardiopulmonary edema and decreased during its resolution.
Moreover, respiratory rate varied with the severity of edema
during both the evolving and the resolution phase.
Many HF patients are implanted with cardioverter defibril-
lators (ICD), or cardiac resynchronization therapy defibrilla-
tors (CRT-D), some of which are capable of monitoring res-
piration in an ambulatory setting. The purpose of this analysis
is to evaluate respiratory rate trends before HF hospitalization
and assess its prognostic value in identifying impending HF
hospitalizations.
2 Methods
NOTICE-HF (Next Generation INCEPTA TM ICD and CRT-
D Field Following Study: Respiratory Rate Trend Evaluation
in Heart Failure Patients) was a prospective international
multi-center study. The purpose of the study was to evaluate
and document appropriate clinical performance of the INCE
PTATM ICD and CRT-D systems, and to demonstrate the clin-
ical relevance of chronic ambulatory daily respiratory rate
trend (RRT) in HF patients. Twenty-five centers from 13
countries in Europe and Asia participated in the study. The
study protocol was approved by appropriate regulatory bodies
and the ethical committee of each center as applicable. The
study was registered on clinicaltrials.gov (identifier
NCT01227785).
Patients who were 18 or older, willing to participate and
indicated for ICD or CRT-D were implanted with INCE
PTATM. After enough ICD patients were enrolled for clinical
performance evaluation, only NYHA Class III patients were
enrolled in the study to maximize the number of HF events
captured during follow-up. Patients who received routinely
scheduled intravenous (IV) inotropic therapy in the last
90 days, prescribed positive airway pressure therapy, had a
life expectancy of less than 1 year, or were NYHA class IV
during the last 4 weeks were excluded from the study.
The device is capable of collecting three daily RRT metrics
up to a year: maximum (maxRR), median (medRR), and min-
imum (minRR). The device and clinical data were collected at
1-, 3-, 6- and 9-month follow-up visits. A HF event was de-
fined as follows: patients had signs and/or symptoms of HF
and one of the following: (1) received unscheduled IV therapy
without hospital admission, (2) was admitted to the hospital
with a calendar date change and received additional HF treat-
ment. All HF events were reported through case report forms
and adjudicated by a Boston Scientific internal clinician who
was blinded to the device data.
3 Statistical analysis
Mean and standard deviations (SDs) of the three RRT metrics
during a 9-month follow-up were calculated for each patient.
In patients who experienced a HF event (HFE group), this
calculation excluded data from 30 days prior to the event to
14 days after the event. In patients who completed the study
without a HF event (nHFE group), all data were used. Stu-
dent’s t test was used to compare the two groups.
We also retrospectively evaluated changes in RRT
(ΔmaxRR, ΔmedRR, ΔminRR) during the 4-week period
before the HF event in HFE group. For this analysis, a 5-day
moving average filter was applied to each trend parameter.
One-tailed Student’s t test was used to evaluate if values at
3 weeks, 2 weeks, 1 weeks and 1-day before HF events were
significantly elevated compared to the baseline defined as
4 weeks prior to a HF event. Events with less than 28 days
of pre-event data were excluded from the analysis. A p value
<0.025 was regarded statistically significant.
We further evaluated the potential of using RRT to assess
the 30-day risk of experiencing worsening HF. Data were
divided into sequential 30-day periods beginning at enroll-
ment. Six risk indices were calculated for each 30-day period
(evaluation window) and compared to a threshold to deter-
mine if the patient was at low or high risk for HF events in
the next 30-day period (observation window). An empirical
threshold was chosen to maximize the separation between two
groups. The incidence of HF events in each observation win-
dow was calculated in low- and high-risk groups and com-
pared using a negative binomial test (Fig. 1). A proportional
means model was used to quantify the association between
each monthly HF event risk and the percentage of event-free
patients observed within the corresponding observation win-
dow. Repeated measurements within patient are accounted
using the proportional means model with sandwich covari-
ance estimation [13]. To calculate the event-free period, only
the first HF event in each observation window was included.
Hazard ratios (HRs), 95 % confidence intervals (CIs) and p-
values were reported using the proportional means model in
both contexts before and after adjusting for clinical variables
that differed at enrollment.
The performance of risk indices that were statistically sig-
nificant between high and low risk groups (p<0.05) were
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further evaluated using a binary classification test. A risk as-
sessment was excluded from the analysis if either its evalua-
tion window had less than 14 days of data or its observation
window was shorter than 30 days. A high HF event risk as-
sessment was classified as true positive (TP) if there was at
least one HF event within its observation window, otherwise it
was classified as false positive (FP). Low HF event risk as-
sessments with HF event-free observation windows were clas-
sified as true negative (TN), otherwise they were classified as
false negative (FN). Sensitivity was calculated as the number
of TP divided by the number of observation windows with at
least one HF event. Specificity was calculated as the number
of TN divided by the number of HF event-free observation
windows. Positive predictive value (PPV) was calculated as
the number of TP divided by the number of high HF event risk
assessments. Negative predictive value (NPV) was calculated
as the number of TN divided by the number of low HF event
risk assessments.
4 Results
There were 120 patients enrolled and implanted with the de-
vice in the study between November 2010 and February 2011.
Seventeen HF events occurred in 13 patients during the 9.2±
0.5 months of follow-up, 4 of which occurred within 28 days
of implant. Patient demographics, medical history, and medi-
cation for the HFE and nHFE groups are shown in Table 1,
where continuous variables are presented as means and SDs,
and categorical variables are presented as frequencies and per-
centages. All patients enrolled had at least New York Heart
Association (NYHA) class I HF. While all patients who had
experienced a HFE were class III at enrollment, NYHA class
and LVEF were not significantly different between the HFE
and nHFE group. Patients in the HFE group had a higher
resting heart rate and a lower blood pressure, as well as more
cardiac surgery, anemia, and different prior hospitalization
status.
Mean and SD of RRTs during the study are summarized in
Fig. 2 for each group.Mean of all three daily RRTmetrics was
similar in HFE and nHFE groups. SD of daily medRR was
significantly higher in the HFE group (1.5±0.4 vs. 1.1±0.4
breaths (br)/min, p<0.01), while SD of daily maxRR and
minRR was not.
Figures 3 and 4 show case examples of the three RRT
metrics in patients with and without HF events. Figure 3
shows RRTs in a patient without HF admissions. All three
RRT metrics were stable during the study. Consistent with
the group analysis of SDs, the case data illustrate the greater
day-to-day variation in maxRR and minRR (shown in the
background of figures using dotted lines) as compared to
medRR. Figure 4 shows RRTs in a patient with a HF admis-
sion. All three RRT metrics were clearly elevated during the
month before the admission.
Aggregated changes in three RRT metrics during a 4-week
period prior to HF events are shown in Fig. 5. A ramp-up
pattern was observed leading up to HF events. All three met-
rics were significantly elevated the week before HF events,
compared to a baseline of 4-week before HF events
(ΔmaxRR, 1.8±3.0; p=0.02; ΔmedRR, 2.1±2.8; p=0.007;
ΔminRR, 1.5±2.1, p=0.008).
In order to assess the risk of experiencing HF events in next
30 days, monthly RR assessments were evaluated. There were
923 total HF event risk assessments (7.7±2.4 assessments per
patient; range 1 to 10 per patient). Of all the monthly assess-
ments, 18 assessments in 11 patients had less than 14 days of
Fig. 1 A schematic plot of the
HF risk analysis schedule. Each
monthlyHF event risk assessment
is calculated using RR collected
during a 30-day evaluation period
and is compared to the number of
protocol-defined HF events
during a subsequent 30-day
observation period
J Interv Card Electrophysiol (2015) 43:21–29 23
data for the calculation of the risk index and 105 additional
assessments in 105 patients had less than 30 days in the fol-
lowing observation window. The remaining 800 HF event risk
assessments in 111 patients (7.2±1.5 per patient, range 2 to10,
with 11 HF events in 9 patients) were considered complete
and were analyzed. A proportional means model with
Table 1 Patient baseline characteristics
Patient baseline characteristic nHFE (N=107) HFE (N=13) p value
Age at implant (years) 65.1±10.6 70.8±7.7 0.07
Gender (M/F) [N (%)] 89 (83)/18 (17) 11 (85)/2 (15) 0.90
Device (CRT-D/ICD) [N (%)] 67 (63)/40 (37) 10 (77)/3 (23) 0.31
NYHA class (I/II/III) [N (%)] 3 (3)/10 (9)/94 (88) 0 (0)/0 (0)/13 (100) 0.41
LVEF (%) 27.7±9.9 25.8±6.5 0.51
QRS duration (ms) 136±35 134±24 0.81
Heart rate at rest (bpm) 70±16 82±20 0.01
Body mass index (kg/m2) 28.1±5.3 27.8±4.0 0.80
Systolic blood pressure (mmHg) 125±18 116±23 0.07
Diastolic blood pressure (mmHg) 73±10 67±8 0.04
Medical history [N (%)]
Ischemic/dilated cardiomyopathy 53 (50)/47 (44) 9 (69)/4 (31) 0.90
Coronary artery disease 48 (45) 8 (62) 0.26
Hypertension 66 (62) 9 (69) 0.60
History of cardiac surgery 33 (31) 8 (62) 0.04
Diabetes 36 (34) 5 (38) 0.73
Renal disease 25 (23) 5 (38) 0.24
COPD 15 (14) 2 (15) 0.89
Asthma 6 (6) 1 (8) 0.76
Anemia 0 (0) 1 (8) 0.004
Pulmonary hypertension 8 (7) 5 (38) <0.001
Hyperlipidemia 42 (39) 6 (46) 0.63
Hospitalizations in last 12 months (yes/no/unknown) 31 (29)/64 (60)/ 12 (11) 3 (23)/4 (31)/ 6 (46) 0.004
Medication [N (%)]
Beta blocker 94 (88) 12 (92) 0.64
Diuretics 90 (84) 12 (92) 0.43
ACE inhibitor 77 (72) 10 (77) 0.71
Aldosterone antagonist 45 (42) 6 (46) 0.78
Angiotensin receptor blocker 23 (21) 3 (23) 0.90
Anti-arrhythmic drugs 11 (10) 2 (15) 0.58
Other 50 (47) 5 (38) 0.57
Fig. 2 Mean and SD RR during
the study (for the HFE group, data
between 30 days prior to and
14 days post HF events were
excluded from the analysis)
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sandwich covariance estimation was used to assess the hazard
ratio and showed significant separation between patients with
high HF risk and those with low HF risk when using the SD of
medRR. A threshold of 1.0 br/min was found to maximize the
separation between two groups. Figure 6 shows the monthly
assessment results from the proportional means model of
event-free time using the SD of medRR. The proportional
means model estimated a 12.3-fold increased risk of
experiencing a HF event within the next month for patients
with high risk indices (HR=12.3, 95%CI 2.57–59, p=0.002).
The risk remained high (HR=8.9, 95%CI 1.75–45, p=0.008)
after adjusting for clinical variables that differed at enrollment,
including heart rate at rest, diastolic blood pressure, history of
cardiac surgery, anemia, and pulmonary hypertension. Event
rates were also significantly higher in the high risk group and
were 0.503 and 0.042 per patient-year in each group, respec-
tively (p=0.002).
Out of the 800 HF risk assessments, 218 were in the high
risk group (above the threshold) with nine HF events occurred
during the observation windows and 582 in the low risk group
(below the threshold) with two HF events in the observation
windows. The risk stratification algorithm has a sensitivity of
81.8%, a specificity of 73.5%, a NPVof 99.7%, and a PPVof
4.1 %. Out of 209 FP risk assessments, 66 (32 %) had other
Fig. 3 Respiratory rates in a
patient without HF admissions.
From top to bottom: daily
maximum, median, and minimum
respiratory rates. Thin lines with
markers: daily trends; thick lines:
5-day moving averages
Fig. 4 Respiratory rates in
patient with a HF admission.
From top to bottom: daily
maximum, median and minimum
respiratory rates. Thin lines with
markers: daily trends; thick lines:
5-day moving averages Dotted
line indicates the day of HF
admission.
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types of adverse events (AE) in either evaluation or observa-
tion window: 26 (12 %) had at least one non-HF AE in the
observation window, 46 (22 %) had at least one AE in the
evaluation window, and 6 (3 %) had AEs in both windows.
The stratification results suggested that patients with a high
standard deviation in daily median RRT had a significantly
increased risk of a HF event within the month following a risk
assessment. However, the calculation of standard deviation
may not be easy for clinicians when reviewing patient’s lon-
gitudinal RRT data. We therefore evaluated an alternative way
to estimate an effective data range by calculating the range of
the data after removing the two largest and two smallest data
points every month. With a threshold of 3 br/min, the range
also showed a strong stratification power to identify patients
Fig. 5 Changes in respiratory
rate metrics prior to a HF event
Fig. 6 The results of the
proportional means model of
event-free time using standard
deviation of respiratory rate
during the evaluation periods
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with high risk of HF events (HR=4.8, 95 % CI 1.5–15, p=
0.007). After adjusting for key clinical variables, the risk
remained high (HR=7.3, 95 % CI 2.3–24, p<0.001).
5 Discussion
We have evaluated changes in the ambulatory respiratory rate
leading up to HF hospitalization. Daily maximum, median,
and minimum respiratory rates were elevated during the 30-
day period leading up to HF events, indicating most patients
experienced respiratory distress before HF admission. Page
and colleagues reported elevated minute ventilation during
rest and exercise observed prior to HF events [14]. However,
changes in the respiratory rate were not reported. In our study,
maximum respiratory rate showed a small drop 2–3 weeks
before HF events (yet not statistically significant). This was
mainly driven by a few patients whose maxRRs dropped due
to a decrease in activity levels during this period. The activity
level, however, was not statistically different prior to HF
events. This observation was consistent with a larger study
using similar device diagnostics in NYHA class I–IV patients
with a CRT-D device [15]. Besides changes in respiratory rate,
other metrics may also be used to quantify the trend leading up
to HF events, such as slope of respiratory rate. We have pre-
viously reported that rates of change in daily maxRR, medRR,
and minRR 30 days before HF events were significantly
higher than that observed before a random time in the non-
HF event group [16].
Of the six risk indices evaluated, only the standard devia-
tion of daily median respiratory rates showed statistical signif-
icance in 30-day HF admission risk stratification. After
adjusting for clinical variables that differed at baseline, pa-
tients with a higher daily variation in median respiratory rate
still had a ninefold increased risk of experiencing a HF event
within the next 30 days compared with those with a lower
daily variation. This was consistent with the fact that standard
deviation of medRR was also the only measure that was sig-
nificantly higher in the group that experienced a HF event than
the group that did not. Physiologically, medRR typically re-
flects the resting respiratory rate of the patient. A higher var-
iation in medRR may indicate that the patient is not in a very
stable condition, thus indicating a higher risk for worsening
HF.
Based on a threshold of 1.0 br/min for the 30-day standard
deviation of medRR, this metric correctly identified 73 % of
patient-observations with HF events (TPs), all of which had
signs of pulmonary congestion or symptoms of shortness of
breath. On the contrary, these signs and symptoms were ab-
sent in the three patient-observations followed by a HF event
in the next 30-day that were not correctly identified (FNs).
Clinically, these three patients did not suffer from shortness
of breath, which is in line with the respiratory rate pattern
recorded. However, in all three cases, individual weight mea-
surements and device-based detection of arrhythmia burden
might have been helpful to identify these patients,
underscoring the importance of combining multiple measure-
ments in heart failure patients.
Of all 800 patient observations, the numbers in the high and
low risk groups were 27.3 and 72.7 %, respectively. The dif-
ference was more than threefold. Of those low-risk patient-
observations, only three were followed by a HF event in the
following month (99.7 % NPV), indicating this metric has a
very high negative predictive power. Since the trends are en-
abled by the implanted devices and available via remote mon-
itoring system, they could be a useful screening tool to enable
clinicians to identify patients who need closer monitoring,
thus focusing limited healthcare resources on the patients
who are at higher risk of decompensating. From a clinical
perspective, remote monitoring of HF patients is transitioning
from a “crisis prediction” regime to a “health maintenance”
regime [17]. Using the negative predictive power of respira-
tory rate analysis in heart failure patients, this may be used in
combination with other measures to distinguish stable patients
from those at risk.
Approximately 95 % of patient-observations in the high
risk group did not experience a HF event during the following
30-day window. Of these, about 34 % experienced other types
of adverse events related to patient conditions either during the
evaluation or the observation period. This indicated that respi-
ratory rate is a very sensitive vital sign, but not specific to one
pathological condition, just like any single sensor. Physicians
need to incorporate respiratory rate with other clinical assess-
ments before making a clinical decision or therapy
adjustment.
Standard deviation is a statistical term that is easy to under-
stand, but not necessarily easy to estimate when reviewing the
trends. To translate it into a measure that is more easily
assessed visually on a display, we evaluated the stratification
ability of a range measure. A simple calculation of data range
subtracting a minimal value from a maximal value is vulner-
able to outliers, while the range after removing the two largest
and two smallest values avoids the problem. Both range mea-
sures were able to identify patients at a higher risk of
experiencing worsening HF in the next 30 days when
medRRT had a range larger than 4 br/min in the 30-day eval-
uation window. The standard deviation had a better discrimi-
natory power than the range measure. This is due to the reso-
lution of the RRT metrics reported by the device (1 br/min),
which limits the resolution of the range measure.
There have been a number of publications that evaluated
the performance of combined diagnostics from implanted de-
vices to stratify a short-term risk for HF hospitalization or
readmission [18–22]. PARTNERS-HF [18] is a prospective
study that evaluated the stratification power of combined de-
vice diagnostics, including fluid index, atrial fibrillation
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burden, bi-ventricular pacing, heart rate, and heart rate vari-
ability. Patients with a positive combined HF device diagnos-
tics had a 5.5-fold increased risk of HF hospitalization with
pulmonary signs or symptoms within the next month. A cou-
ple of recent publications confirmed the approach using
Bayesian model [19] and showed value in 30-day readmission
risk stratification using these diagnostics [20]. The best risk
score from these studies yielded a HR of 10 for 30-day HF
hospitalization when comparing high-risk group to low-risk
group and a HR of 2.1 when comparing medium-risk to low-
risk. In our study, we were able to demonstrate a performance
similar to the combined diagnostics using only respiratory rate
trends, suggesting respiratory rate would add significant value
in such an approach. Preliminary results from another study
evaluating existing device diagnostics [21, 22] haven shown
an improved risk stratification power combining respiratory
rate with other device diagnostics such as pacing and shock
lead impedance, activity, heart rate, atrial arrhythmia burden,
weight, and % biventricular pacing.
6 Limitations
The study is small, especially in terms of the number of HF
events; the majority of the patients are NYHA class III; HF
events were not adjudicated by an independent clinical event
committee; and the analysis was retrospective in nature and
was not tested in an independent data set. Larger studies are
needed to validate these preliminary observations. While it is
useful to have a good negative predictive marker, clinically, it
is also relevant to have a consistent marker detecting early
signs of worsening heart failure that could indicate a need
for intervention to prevent hospitalization.
7 Conclusions
Daily maximum, median, and minimum respiratory rates are
significantly elevated prior to HF events. Patients with a
higher day-to-day variability in median respiratory rate were
at increased risk of experiencing a HF event. Ambulatory
daily respiratory rate trends may be a valuable addition to
standard management for HF patients in order to pre-empt
significant decompensation and hospitalization.
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